

August 11, 1969

Dr. Allen P. Borger
Associate Director
Department of Clinical Research
Chas. Pfizer & Co., Inc.
Groton, Connecticut 06340

Dear Dr. Borger:

The NDA summary volume for thiothixene oral concentrate was read with considerable interest. I have reviewed the clinical data and find that the data is consistent with the following conclusions:

1. Thiothixene concentrate is an active psychoactive agent - the patients exhibiting decreased psychotic symptoms, parkinsonism and sedation. These features were reported in all studies in which daily doses above 20 mg/day were used. The symptoms were equivocal at lower levels.
2. The two studies which compared the clinical efficacy of capsules thiothixene and oral concentrate reported similar clinical effects at comparable dosages.
3. Tables of the reported secondary effects of both forms (capsules and oral concentrate) show the same patterns of effects with a similar incidence.

Furthermore, the dosages, clinical and secondary effects of the reports of oral concentrate are similar to our own studies of thiothixene in capsules reported in 1967, and I would have no hesitancy in undertaking clinical trials of the concentrate in treating schizophrenia at dosages comparable to thiothixene capsules.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp